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Abstract: 
The central nervous system (CNS) is a large network of intercommunicating cells that 
function to maintain tissue health and homeostasis. Considerable evidence suggests 
that glucocorticoids exert both neuroprotective and neurodegenerative effects in the 
CNS. Glucocorticoids act by binding two related receptors in the cytoplasm, the 
mineralocorticoid receptor (MR) and the glucocorticoid receptor (GR).  The 
glucocorticoid:receptor complex then mediate cellular responses by transactivating 
target genes or via protein:protein interactions. The paradoxical effects of 
glucocorticoids in mediating survival and death of neurons have been attributed to the 
concentration and the ratio of mineralocorticoid to glucocorticoid receptor activation. 
Glucocorticoid induced leucine zipper (GILZ) is a recently identified protein 
transcriptionally upregulated by glucocorticoids. It is constitutively expressed in many 
tissues including brain. Functionally while GILZ mimics many of the beneficial effects of 
glucocorticoids including the anti-inflammatory and anti-proliferative potential, it 
suppresses the adverse effects of glucocorticoids presumably by exerting differential 
effects on lineage development by pluripotent cells.  As opposed to glucocorticoids, 
GILZ downregulates the adipogenic transcription factor peroxisome proliferator-
activated receptor (PPAR)-and upregulates runt-related transcription factor 2 
(RUNX2) widely implicated in osteogenesis and more recently in neurogenesis as well.  
Further, data on GILZ expression and effects following induced stress or spinal cord 
injury suggest potential roles in CNS diseases. Here we provide a short overview of 
GILZ expression in CNS health and discuss three potential rationales for its role in the 
pathogenesis of Alzheimer’s disease, a common neurodegenerative pathology.  
Introduction: 
I. Glucocorticoids in the central nervous system (CNS): 
Glucocorticoids (corticosterone in rodents and cortisol in humans) secreted in response 
to stress induced activation of the hypothalamo-pituitary-adrenal (HPA) axis exert a 
wide range of actions on most cell types including the cells of the central nervous 
system (CNS) [1, 2]. Upon binding the mineralocorticoid receptor (MR) or the 
glucocorticoid receptor (GR) in the cytoplasm, the glucocorticoid:receptor complex 
translocate to the nucleus and mediate cellular responses by genomic mechanisms via 
specific glucocorticoid response elements (GRE) in the DNA or by non-genomic 
protein:protein interactions. The receptors shuttle between the cytoplasm and the 
nucleus; their subcellular localization being determined by the equilibrium between 
nuclear import and export [3]. The negative feedback and circadian rhythmicity of 
circulating glucocorticoids are critical for maintaining the basal HPA axis activity and 
facilitate the termination of HPA activation [3, 4].  
 
Glucocorticoids exhibit ten-fold higher affinity for MR than GR [5, 6].  This one ligand/ 
two receptor system works in balance, modulating a large spectrum of actions in the 
CNS. While MR is highly expressed in limbic areas such as the hippocampus and 
amygdala; GR is ubiquitously expressed throughout the brain [7, 8]. Sensitivity to 
glucocorticoids depends on the concentration and duration of exposure, bioavailability 
and the density of receptors. In physiological conditions and during circadian trough the 
high affinity MR is preferably occupied with less than 10% GR occupancy to help 
maintain low basal glucocorticoid levels [3, 9]. Several studies suggest that the MR 
functionality is important for maintaining the basal HPA activity and preserving the 
normal metabolism of the neurons [10, 11]. Pathological effects of glucocorticoids are 
largely mediated by GR. While both receptors can modulate transcription of the same 
target genes, microarray studies suggest that approximately 20% of the expression 
profiles are uniquely modulated by GR [12]. This is largely attributed to the non-genomic 
functions, wherein nuclear GR tethers to and interferes with the functioning of other 
transcription factors such as nuclear factor-kappa B (NF- and activator protein 1 
(AP-1) [8, 13].  
 
I.a: Glucocorticoids in Alzheimer’s disease 
Both lack and overexposure of glucocorticoids increases the risk for neurodegenerative 
diseases. Excessive glucocorticoid alters MR/GR ratio, disrupts nucleocytoplasmic 
shuttling of the receptors and dysregulates HPA activity [1, 4]. Clinical observations of 
elevated plasma cortisol and/or changes in circadian rhythm of glucocorticoid release in 
Alzheimer’s disease (AD) and Parkinson’s disease (PD) support a role for high 
glucocorticoids in neurodegenerative pathologies [14-16]. In AD patients, the higher 
plasma glucocorticoids correlated with decreased hippocampal volume, a region of the 
brain critical for learning and memory [15, 16]. Mechanistically, highly elevated 
glucocorticoids have been shown to accelerate the beta amyloid (A) plaque formation 
and tau phosphorylation, two major pathological hallmarks of AD, and thereby enhance 
the vulnerability of neuronal cells to toxic stimuli [17]. In triple transgenic mouse model 
of AD which develops both A and tau pathologies in a progressive and region-specific 
manner, dexamethasone treatment upregulated steady state levels of amyloid precursor 
protein (APP), -site APP cleaving enzyme (BACE-1) and enhanced A generation [18, 
19]. Blockade of glucocorticoid:GR but not glucocorticoid:MR interaction abrogated the 
dexamethasone mediated upregulation of A secretion [20]. 
  
Both stress and A aggregates precipitate oxidative stress, considered as one of the 
early events in AD pathology as evidenced by the increased presence of reactive 
oxygen species in vulnerable neurons [21, 22]. Chronic stress has been shown to 
increase lipid peroxidation in the hippocampus in normal and AD mice with three fold 
higher upregulation in the diseased animals [23]. It has been observed that the oxidative 
stress mediate negative regulation of GR and allow retention of the glucocorticoid:GR 
complex in the cytoplasm [23, 24]. This reduces the ability of glucocorticoids to repress 
transcription factors NF- and AP-1 leading to inflammatory distress. Increased 
oxidative stress further enhances A accumulation initiating a vicious cycle [21]. In AD 
mice, the A induced oxidative stress could be suppressed by pharmacological 
blockade of corticosterone release suggesting that the elevated glucocorticoids and A 
act synergistically to enhance the vulnerability of neurons to apoptosis [20].  
 
II. Glucocorticoid induced leucine zipper (GILZ) 
GILZ is a recently identified protein that has been shown to mediate many of the cellular 
effects of glucocorticoids. It is a member of the TSC22D (transforming growth factor β1-
stimulated clone 22 domain) family of proteins that potentially impact multiple biological 
processes [25, 26]. Four different isoforms have been identified arising as splice 
variants from a single gene [27]. Structurally, the GILZ protein has an amino terminal 
leucine zipper motif for dimerizing and a carboxy terminal proline rich region for protein-
protein interactions [25, 26]. Constitutive expression of GILZ has been reported in many 
cell types and multiple organs including skeletal muscle, lungs, intestine, kidney and 
brain [27]. With six GRE in its promoter region, GILZ is strongly induced by 
glucocorticoids [25]. Much like other glucocorticoid responsive genes such as the 
tyrosine aminotransferase, glutamine synthetase, cholesterol-7-hydroxylase and the 
glucocorticoid receptor, GILZ exhibits circadian rhythm of expression in response to the 
rhythmic release of endogenous glucocorticoid [27]. 
 
II.a. GILZ in the CNS 
Endogenous GILZ is widely expressed throughout the brain and spinal cord 
suggesting a physiological role in the CNS [27]. In mice exposed to water immersion 
restraint stress, activation of HPA activity and increased glucocorticoid secretion 
correlated with elevated GILZ expression in medial pre-frontal cortex and hippocampal 
neurons [28, 29]. The stress induced GILZ upregulation was abrogated in 
adrenalectomized mice attributing the response to the increase in glucocorticod:GR 
mediated transactivation [29]. Constitutive expression of GILZ has been observed in 
murine microglial cells. Further, similar to the observations in macrophages and 
lymphocytes, microglial GILZ expression correlated negatively with inflammatory 
cytokines and was downregulated following induced anxiety [28, 30]. 
 
III. Plausible roles of GILZ in AD 
Three distinct rationales are postulated for potential roles of GILZ in AD pathogenesis. 
1) A role in A regulation supported by the ubiquitous expression of GILZ in neurons 
and glia [27, 29]; 2) GILZ as an anti-inflammatory molecule that modulates the 
processes of neuroinflammation and neurodegeneration in AD [31, 32]  and 3) a role in 
neurogenesis based on potential cross-talk between GILZ and other nuclear 
transcriptional hormone receptors such as peroxisome proliferator-activated receptor 
(PPAR)- and CCAAT/enhancer-binding protein (C/EBP)- [33].  
 
Hypothesis 1: Constitutive GILZ regulates physiological A in CNS health. 
Normal brain contains both soluble and neuronal A. Picomolar concentration of A 
exhibit neurotrophic properties, promote neurogenesis and contribute to normal synaptic 
activity and memory [34]. Mechanistically physiological A has been shown to mediate 
tyrosine phosphorylation and increase phosphatidylinositol-3-kinases (PI3K) activity in 
neuronal cells [22, 35, 36]. The PI3K pathway has been implicated in modulating 
autophagy, neuronal survival, neurite extension and synaptic plasticity in the brain.  
Blockade of this pathway has been shown to increase apoptosis in A exposed 
neuronal cells [37, 38]. 
 
As stated above, considerable data suggest essential roles for MR, the high affinity 
receptor for glucocorticoids, in neuronal survival and neurogenesis [10]. In health under 
low GC conditions, ligand activated MR not only induces BACE-1 transcription and 
inflammatory cytokines that facilitate A production, but also upregulates many 
neuroprotective molecules [4, 39]. In PC12 neuronal cells overexpression of MR has 
been shown to enhance neuron specific genes such as microtubule  associated protein-
2 (MAP2) and -tubulin III, increase the ratio of anti-apoptotic (Bcl2 and BclxL) to pro-
apoptotic (Bax and Bak) proteins and diminish caspase 3 cleavage [40, 41]. While 
exposure to A reduced MR and increased nuclear GR in cultured rat hippocampal and 
cortical neurons with consequent increase in cell death, activation of MR reduced the 
vulnerability of the cultured neurons to apoptosis [41, 42]. Tauroursodeoxycholic acid 
(TUDCA), a cholesterol derived endogenous molecule, has been shown to exhibit 
neuroprotective effects by selectively binding MR and increasing its nuclear 
translocation with subsequent transactivation of Bcl-2 and other anti-apoptotic genes 
[43]. It has been suggested that an optimal balance between MR and GR activation with 
MR predominating in the hippocampus is necessary for best emotional and cognitive 
function [1, 10, 11].  
 
GILZ is one of the transcripts upregulated by both MR and GR [31, 44]. Mechanistically 
much like glucocorticoids, GILZ has been shown to enhance expressions of anti-
apoptotic molecules such as Bcl-2 and Bcl-XL in different cell types including 
cardiomyocytes, epithelial cells and many human cancer cells [31, 45-47]. GILZ has 
also been shown to modulate the PI3K pathway, suppress cytokines and inhibit 
inflammation in activated lymphocytes and epithelial cells [48, 49]. Taken together it is 
plausible that the constitutive GILZ induced in neuronal cells under low GC conditions 
may act in concert with picomolar A in regulating autophagy and neuronal survival by 
increasing anti-apoptotic factors and suppressing excessive cytokines. Furthermore, 
since PI3K signaling has been shown to play critical roles in regulating survival of A 
exposed neurons, it is tempting to speculate that the regulation of PI3K signaling by 
constitutive GILZ in neurons may indirectly control the threshold of A accumulation and 
CNS health.  
 
Hypothesis 2: Exogenous GILZ is an attractive strategy to suppress neuroinflammation. 
Neuroinflammation plays critical roles in the initiation and/or progression of most 
neurodegenerative diseases including AD [50-52]. Aging and chronic stress are 
significant risk factors. In addition, persistent stress mediated increase in glucocorticoids 
enhances the neuronal cell vulnerability to glutamate, the excitatory neurotransmitter 
and A induced neurotoxicity [1, 19].  A exposure activates the p65:p50 NF- dimers 
in glia and post-mitotic neurons and enhance transactivation of inflammatory and 
apoptotic genes [53]. Elevated Bax (pro-apoptotic) to Bcl-2 (anti-apoptotic) ratio has 
been observed in A stimulated neuronal cells [54-56]. Increased presence of IL-1β, IL-
6, and TNF- has been reported in the affected tissues, serum and cerebrospinal fluid 
of AD patients [57]. However, exogenous glucocorticoids, the prototype anti-
inflammatory agents have been largely ineffective and even counter-productive in the 
treatment of AD. The low therapeutic efficacy of glucocorticoids is correlated with a 
disproportionate increase in the glucocorticoid:GR complex with enhanced susceptibility 
to apoptosis [58].  
 
GILZ represents a potentially efficacious alternative anti-inflammatory molecule to 
suppress neuroinflammation. Mechanistically the anti-inflammatory and anti-apoptotic 
effects of both glucocorticoids and GILZ are largely attributed to the suppression of NF-
 mediated transactivation [59, 60]. While the glucocorticoid:GR complex tether to and 
interfere with NF--DNA binding, GILZ binds to and sequesters the p65 subunit of NF-
 in the cytoplasm, thereby preventing nuclear translocation and transactivation of 
pathological mediators [7, 26, 61]. Overexpression of GILZ has been shown to suppress 
inflammatory cytokines and ameliorate pathology in models of colitis, multiple sclerosis 
and spinal cord injury [32, 62, 63]. We observed that selective blockade of activated p65 
by as a synthetic peptide mimic of the p65 binding domain of GILZ suppressed A 
mediated toxicity in neuroblastoma cells and in primary human neuronal  cells [64, 65]. 
Taken together, it is hypothesized that by virtue of binding the transactivation domain of 
p65 exposed only in activated cells, exogenous GILZ represents an attractive strategy 
to suppress neuroinflammatory-neurodegenerative diseases including AD (Fig 2).          
  
Hypothesis 3: GILZ plays a role in neurogenesis. 
Neurogenesis involves proliferation, survival, migration and lineage differentiation of 
neural stem/progenitor cells. Continuous stimulation including cognitive functions elicits 
protective responses that avoid tissue damage, promote neurogenesis and maintain 
homeostasis in the CNS. This involves complex signaling pathways that are interlinked 
and tightly regulated [66]. Glucocorticoid and NF- signaling are two cross-talking 
pathways shown to play crucial roles in adult neurogenesis [67, 68]. In health, 
stimulation of NF- signaling by low concentrations of proinflammatory cytokines such 
as TNF- or the excitatory neurotransmitter glutamate has been shown to increase 
proliferation and differentiation of neural stem cells and promote neuronal survival [67, 
69]. It has been suggested that neuroprotection is largely attributed to the activation of 
NF- C-rel dimers [70]. Similarly at physiological concentrations, glucocorticoids 
signaling via MR increased the proliferation and differentiation of human hippocampus-
derived stem cells. However, excessive inflammation or high glucocorticoids largely 
inhibited neuronal stem cells [68, 71]. GILZ as an interface molecule that connects 
glucocorticoid and NF- pathways could potentially play a role in modulating the 
neural stem cell responses and hence neurogenesis [59].    
 
In addition to NF-, the GILZ also interacts with other transcription factors implicated in 
adult neurogenesis, the PPAR- and C/EBP- [72, 73]. The basal expression of both 
C/EBP and PPAR- in the adult CNS is relatively low [74, 75]. While NF- activation 
and cytokines such as TNF- enhance C/EBP expression, sustained elevation of 
inflammatory cytokines suppress its transcription [76]. Glucocorticoids enhance the 
transcription of both C/EBP and PPAR- [77, 78]. Further, C/EBP has also been 
shown to bind the C/EBP binding elements in PPAR-promoter and upregulate its 
transcription [75, 76]. Several reports substantiate a neurogenic role for PPAR-. 
Activation of PPAR- in neural stem cells has been shown to promote differentiation to 
mature neurons, astrocytes and oligodendrocytes [74]. Treatment with PPAR- agonists 
has been shown to induce neurite outgrowth and increased axonal length in 
hippocampal neurons [79].  
 
GILZ has been shown to bind a tandem repeat of C/EBP binding sites and act as a 
sequence-specific trans-repressor of PPAR- in pluripotent mouse mesenchymal stem 
cells [33]. In human bone marrow derived stem cells dexamethasone induced GILZ has 
been shown to suppress PPAR-2 and upregulate RUNX-2 transcription factor [73, 80]. 
Although a plethora of studies substantiate the critical involvement of RUNX2 in 
osteogenesis, recent reports suggest a potential role for the molecule in neuronal 
development [81]. Adult human hippocampus and cultured rat astrocytes have been 
shown to express RUNX2 transcript [82, 83]. In human astroglioma cells RUNX2 is 
significantly elevated and regulates the expression of galectin 3, a  galactoside-binding 
lectin that has been shown to promote neural cell adhesion and neurite growth [83].  
 
Collectively, the physical interactions of GILZ with multiple transcription factors greatly 
enhances the number of potentially regulated genes or post-translational modifications 
that could crucially affect molecular mechanisms involved in the dynamic process of 
adult neurogenesis. It is postulated that under low glucocorticoid and inflammatory 
conditions, GILZ could facilitate neuronal differentiation of stem cells and promote 
hippocampal neurogenesis by upregulating RUNX-2 transcription. This is supported by 
the observations of inverse relationship between NF- and RUNX-2 transcription 
factors and elevated RUNX-2 in adult hippocampus [83, 84]. 
 
IV. Conclusion: 
The effects of endogenous and exogenous glucocorticoids in neurogenesis, 
neuroinflammation and neurodegeneration in the CNS have been extensively 
investigated with some mechanistic elucidations, some contradictory findings and some 
as yet unanswered questions. It is tempting to speculate that some of the contradictory 
or unknown glucocorticoids effects could be attributed to the GILZ expression. The 
uneven distribution and upregulated expression following HPA activation suggests 
multiple roles for GILZ in the CNS. Much like its effects on osteogenic differentiation, 
GILZ could potentially play a role in neuronal differentiation and development. In 
microglial cells a tightly controlled and coordinated action of MR and GR has been 
shown to regulate NF- functions [8]. At low ligand concentration or at early time 
points following activation, the effects of MR mediated transactivation of neurotrophic 
factors and anti-inflammatory GILZ could potentially supersede that of BACE1 and pro-
inflammatory cytokines. In conditions of chronic stress and/or A toxicity inflammatory 
mediators suppress GILZ. In this context, exogenous GILZ could represent an attractive 
strategy to suppress neuroinflammation.  In conclusion, elucidation of the physiological 
role of GILZ in the CNS, its induction by other factors including microbial agents or free 
radicals, role in BACE-1 activity and A homeostasis will enhance our understanding of 
the glucocorticoid signaling in the CNS and help in the identification of alternative 
therapeutic strategies to target neuroinflammation and neurodegeneration.    
 
  
Figure legend: 
Fig 1: Schematic representation of potential role of GILZ in regulating physiological 
amyloid beta in CNS health. Low glucocorticoid (GC) and picomolar concentration of 
amyloid beta (A) are features of healthy CNS. Signaling via phosphatidylinositol-3-
kinases (PI3 K) has been shown to critical for neutrophic and anti-apoptotic effects of 
picomolar A. Blockade of PI3 K has been shown to abrogate such effects.  Under low 
GC conditions, MR is preferentially occupied and mediates GILZ expression. In 
lymphocytes and epithelial cells, GILZ overexpression has been shown to suppress PI3 
kinase activity and inhibit inflammatory responses. Micromolar concentration of A is 
associated with enhanced production of anti-apoptotic factors via increased PI3 kinase 
signaling. This figure speculates that constitutive GILZ expression plays a role in 
modulating PI3 K signaling thereby regulating indirectly the physiological A.  
 
Fig 2: Schematic representation of exogenous GILZ as a potential therapeutic agent for 
AD. Aging, chronic stress, amyloid b aggregates or other factors mediated oxidative 
stress activate NF-p65 which in turn induces activation of pro-inflammatory 
(cytokines, glutamate) and proapoptotic factors that ultimately lead to cell death. 
Exogenous GILZ will bind p65 and prevent activation of deleterious mediators. 
 
Fig 3: Potential role of GILZ adult neurogenesis:  Schematic representation of some of the 
factors involved in adult neurogenesis. Toll like receptor (TLR) stimulation and cytokines such 
as TNF- activate NF- transcription factor in adult hippocampal neural stem cells. While NF-
C-rel containing dimers are predominantly neuroprotective, p65 containing dimers promote 
transactivation of inflammatory cytokines that upregulate C/EBP  transcription factor which in 
turn induces PPAR-. However, inflammatory cytokines can also downregulate both C/EBP  
and PPAR-. Glucocorticoids induced GILZ expression in neural stem cells can modulate this 
process at two steps (inhibitory actions shown in red): 1) blockade of NF- p65 and 2) 
suppression of PPAR- and transactivation of RUNX-2.  
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